Genetic factors influencing the risk of multiple myeloma bone disease

Leukemia

Volumn 30, Issue 4, 2016, Pages 883-888

  Johnson, D C ^a   Weinhold, N ^b,c   Mitchell, J ^a   Chen, B ^d   Stephens, O W ^b   Forsti A ^d,e   Nickel, J ^c   Kaiser, M ^a   Gregory, W A ^f   Cairns, D ^f   Jackson, G H ^g   Hoffmann, P ^h,i   Noethen, M M ^h   Hillengass, J ^c   Bertsch, U ^c   Barlogie, B ^b   Davis, F E ^b   Hemminki, K ^d,e   Goldschmidt, H ^c,j   Houlston, R S ^a   Morgan, G J ^b   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e LUND UNIVERSITY   (Sweden)

^f UNIVERSITY OF LEEDS   (United Kingdom)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h UNIVERSITY OF BONN   (Germany)

ⁱ UNIVERSITY OF BASEL   (Switzerland)

^j National Center of Tumor Diseases   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11B PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ALLELE; ARTICLE; BONE DISEASE; BONE REMODELING; COHORT ANALYSIS; FEMALE; GENE EXPRESSION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIATION; GENOTYPE; GERM LINE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELOMA CELL; ODDS RATIO; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM; BONE DISEASES; CANCER STAGING; COMPLICATION; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RISK FACTOR;

AGED; BIOMARKERS, TUMOR; BONE DISEASES; FEMALE; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; OSTEOPROTEGERIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS;

EID: 84954533526     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.342     Document Type: Article

References (48)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-1873
2. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060
3. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007; 110: 1860-1867
4. Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006; 108: 3992-3996
5. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420
6. Krall EA, Dawson-Hughes B. Heritable and life-style determinants of bone mineral density. J Bone Miner Res 1993; 8: 1-9
7. Richards JB, Zheng HF, Spector TD. Genetics of osteoporosis from genome-wide association studies: advances and challenges. Nat Rev Genet 2012; 13: 576-588
8. Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Forsti A, et al. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet 2013; 45: 1221-1225
9. Weinhold N, Johnson DC, Chubb D, Chen B, Forsti A, Hosking FJ, et al. The CCND1 c.870G4A polymorphism is a risk factor for t(11; 14)(q13; q32) multiple myeloma. Nat Genet 2013; 45: 522-525
10. Broderick P, Chubb D, Johnson DC, Weinhold N, Forsti A, Lloyd A, et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat Genet 2012; 44: 58-61
11. Erickson SW, Raj VR, Stephens OW, Dhakal I, Chavan SS, Sanathkumar N, et al. Genome-wide scan identifies variant in 2q12.3 associated with risk for multiple myeloma. Blood 2014; 124: 2001-2003
12. Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001; 98: 3534-3540
13. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64: 1546-1558
14. Chiecchio L, Protheroe RK, Ibrahim AH, Cheung KL, Rudduck C, Dagrada GP, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 2006; 20: 1610-1617
15. Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A, et al. Combining information regarding chromosomal aberrations t(4; 14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 2010; 95: 1150-1157
16. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 2009; 5: e1000529
17. Delaneau O, Zagury JF, Marchini J. Improved whole-chromosome phasing for disease and population genetic studies. Nat Methods 2013; 10: 5-6
18. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575
19. R-Core-Team. R. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, ISBN 3-900051-07-0, URL http: //www.R-project.org/, 2013
20. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 2012; 22: 1790-1797
21. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 2012; 40: D930-D934
22. Cooper GM, Goode DL, Ng SB, Sidow A, Bamshad MJ, Shendure J, et al. Single-nucleotide evolutionary constraint scores highlight disease-causing mutations. Nat Methods 2010; 7: 250-251
23. Chng WJ, Santana-Davila R, Van Wier SA, Ahmann GJ, Jalal SM, Bergsagel PL, et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia 2006; 20: 807-813
24. Wu P, Walker BA, Brewer D, Gregory WM, Ashcroft J, Ross FM, et al. A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment. Clin Cancer Res 2011; 17: 6347-6355
25. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, et al. Multiple genetic loci for bone mineral density and fractures. N Engl J Med 2008; 358: 2355-2365
26. Kemp JP, Medina-Gomez C, Estrada K St, Pourcain B, Heppe DH, Warrington NM, et al. Phenotypic dissection of bone mineral density reveals skeletal site specificity and facilitates the identification of novel loci in the genetic regulation of bone mass attainment. PLoS Genet 2014; 10: e1004423
27. Estrada K, Styrkarsdottir U, Evangelou E, Hsu YH, Duncan EL, Ntzani EE, et al. Genome-wide meta-Analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet 2012; 44: 491-501
28. Paternoster L, Lorentzon M, Lehtimaki T, Eriksson J, Kahonen M, Raitakari O, et al. Genetic determinants of trabecular and cortical volumetric bone mineral densities and bone microstructure. PLoS Genet 2013; 9: e1003247
29. Liang L, Morar N, Dixon AL, Lathrop GM, Abecasis GR, Moffatt MF, et al. A crossplatform analysis of 14, 177 expression quantitative trait loci derived from lymphoblastoid cell lines. Genome Res 2013; 23: 716-726
30. Grundberg E, Small KS, Hedman AK, Nica AC, Buil A, Keildson S, et al. Mapping cisand trans-regulatory effects across multiple tissues in twins. Nat Genet 2012; 44: 1084-1089
31. Richards JB, Rivadeneira F, Inouye M, Pastinen TM, Soranzo N, Wilson SG, et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 2008; 371: 1505-1512
32. Rabin N, Kyriakou C, Coulton L, Gallagher OM, Buckle C, Benjamin R, et al. A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer. Leukemia 2007; 21: 2181-2191
33. Rivadeneira F, Styrkarsdottir U, Estrada K, Halldorsson BV, Hsu YH, Richards JB, et al. Twenty bone-mineral-density loci identified by large-scale meta-Analysis of genome-wide association studies. Nat Genet 2009; 41: 1199-1206
34. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319
35. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998; 139: 1329-1337
36. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003; 101: 2094-2098
37. Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 2002; 347: 175-184
38. Ralston SH. Clinical practice. Paget's disease of bone. N Engl J Med 2013; 368: 644-650
39. Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M, et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007; 110: 334-338
40. Bolzoni M, Storti P, Bonomini S, Todoerti K, Guasco D, Toscani D, et al. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myelomainduced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. Exp Hematol 2013; 41: 387-397 e381
41. Olivier S, Close P, Castermans E, de Leval L, Tabruyn S, Chariot A, et al. Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor-kappaB inhibition and gene expression signature. Mol Pharmacol 2006; 69: 1615-1623
42. Sola B, Renoir JM. Estrogenic or antiestrogenic therapies for multiple myeloma?. Mol Cancer 2007; 6: 59
43. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003; 97: 887-892
44. Reddy GK, Nadler E, Jain VK. Denosumab (AMG 162), a Fully Human Monoclonal Antibody Against RANK Ligand Activity. Support Cancer Ther 2005; 3: 14-15
45. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19: 1059-1066
46. Lang R, Gundlach AL, Kofler B. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol Ther 2007; 115: 177-207
47. Adachi H, Tsujimoto M. Characterization of the human gene encoding the scavenger receptor expressed by endothelial cell and its regulation by a novel transcription factor, endothelial zinc finger protein-2. J Biol Chem 2002; 277: 24014-24021
48. Proudfoot D, Davies JD, Skepper JN, Weissberg PL, Shanahan CM. Acetylated lowdensity lipoprotein stimulates human vascular smooth muscle cell calcification by promoting osteoblastic differentiation and inhibiting phagocytosis. Circulation 2002; 106: 3044-3050